Clinical Trial Detail

NCT ID NCT03961698
Title Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

renal cell carcinoma

triple-receptor negative breast cancer

Therapies

Atezolizumab + Bevacizumab + IPI-549

Atezolizumab + IPI-549 + Nab-paclitaxel

Age Groups: adult senior

No variant requirements are available.